In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...
It is estimated that about 800 people with Hodgkin lymphoma could benefit from the decision by the National Institute for Health and Care Excellence.
An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback